Industry media BioPharma Dive recently released a special report, selecting 10 potential clinical trials from numerous ongoing projects that are expected to announce results in the second half of this year. These trials focus on multiple key treatment areas such as obesity, lung cancer, and atopic dermatitis (AD), with some results already disclosed. These studies are expected to bring breakthrough progress to the entire biopharmaceutical industry, further promoting medical innovation and benefiting more patients.
Drug name: Orforglipron (LY3502970)
Indications: Obese or overweight patients with obesity related comorbidities
Development company: Eli Lilly and Company
Clinical trial: Attain-1 (NCT05869903)
Drug name: Amlitelimab
Indication: atopic dermatitis
Development company: Sanofi
Clinical trials: Coast-1 (NCT06130566), SHORE (NCT06224348)
Drug name: Sonelokimab
Indications: hidradenitis suppurativa
Development company: Moonlake Immunotherapeutics
Clinical trials: Vela-1 (NCT06411899), Vela-2 (NCT06411379)
Drug name: Ivonescimab
Indication: Non small cell lung cancer (NSCLC)
Development companies: Summit Therapeutics, Akesobio
Clinical trial: HARMONI (NCT06396065)
Drug name: Fenebrutinib
Indication: Recurrent multiple sclerosis (RMS)
Development company: Roche
Clinical trials: FENhance (NCT04586010), FENhance 2 (NCT04586023)
Drug name: WVE-006
Indication: Alpha-1 antitrypsin deficiency (AATD)
Development company: Wave Life Sciences
Clinical trial: RestorAATion-2 (NCT06405633)
Drug name: Evolocumab
Indication: Hyperlipidemia
Development company: Amgen
Clinical trial: VESALIUS-CV (NCT03872401)
Drug name: VLA15
Indication: Lyme disease
Development companies: Pfizer, Valneva
Clinical trial: VALOR (NCT05477524)
Drug name: BHV-7000
Indication: Depression Disorder (MDD)
Development company: Biohaven
Clinical trial: NCT06419608
Drug name: mRNA-1010
Indication: Seasonal influenza
Development company: Moderna
Clinical trial: P304 (NCT06602024)
<Reprinted from WuXi AppTec>
